Common clinical uses include:
Physicians may choose Avinerve XT when pain has a neuropathic character (burning, electric shocks, tingling, numbness) and when adding neurotropic vitamins is considered helpful.
Q: Is Avinerve XT addictive? A: The anticonvulsant components (pregabalin/gabapentin) are not classical opioids but can cause dependence-like withdrawal if stopped abruptly; follow tapering guidance.
Q: Can I drink alcohol while taking it? A: Avoid or minimize alcohol due to increased sedation and dizziness risk.
Q: How long until vitamins help? A: Neurological recovery from vitamin support may take weeks to months.
Q: Can children take it? A: Use and dosing in children depend on the specific formulation and should be determined by a pediatrician.
Q: What if I miss a dose? A: Take it as soon as you remember unless it’s near the next dose; do not double up—follow prescriber instructions.
Avinerve XT Tablet is a prescription-only medication primarily formulated to manage symptoms associated with nerve damage. The "XT" in its name typically signifies an "Extended Release" or a high-potency, time-tested combination of neurotropic vitamins and supplements. Unlike standard multivitamins, Avinerve XT is a specialized neuropathic formulation designed to repair, regenerate, and protect the peripheral nerves. avinerve xt tablet
It is most commonly prescribed for patients suffering from Diabetic Peripheral Neuropathy (nerve pain due to diabetes), Idiopathic Neuropathy, and nutritional deficiencies affecting the nervous system.
| Aspect | Recommendation | | :--- | :--- | | Medical Supervision | Required (Prescription only). | | Primary Goal | Nerve repair and pain management. | | Key Ingredient | Methylcobalamin (+/- Pregabalin/ALA). | | Dietary Note | Maintain a balanced diet to support absorption. | | Duration | Long-term use is common for chronic neuropathy, per doctor's advice. |
This guide provides a general overview. Please read the patient information leaflet included with your medication for specific details regarding the brand you have been prescribed.
, it is likely a variant or misnomer for one of the following documented medications used to treat nerve-related issues. Apollo Pharmacy Most Likely Product: Avinerve-NT Avinerve-NT
is a common prescription combination used to manage chronic nerve pain. Apollo Pharmacy Composition : Pregabalin (75mg) + Nortriptyline (10mg). Primary Uses Neuropathic Pain
: Treats pain from damaged nerves (e.g., diabetic neuropathy, shingles, or spinal cord injury). Fibromyalgia : Reduces widespread muscle pain and fatigue. Anxiety & Seizures
: Sometimes used for generalized anxiety disorder or specific types of epilepsy. Common Side Effects Common clinical uses include:
: Dizziness, sleepiness, blurred vision, dry mouth, and weight gain. Apollo Pharmacy Other Avinerve Variants
If your tablet contains vitamins or different active ingredients, it may be one of these: Avinerve SR : A sustained-release Vitamin B12
supplement (Methylcobalamin) used to treat B12 deficiency and support nerve health. Avinerve Forte
: A multivitamin supplement containing Alpha-lipoic acid, Methylcobalamin, Folic Acid, Vitamin B6, and Vitamin D3 to protect and repair damaged nerves. Avinerve-D : A combination of Pregabalin Duloxetine specifically for diabetic nerve pain and fibromyalgia. Important Safety Information Medical Supervision
: These medications must only be taken as advised by a doctor. Do not stop taking them suddenly, as it may cause withdrawal symptoms like nausea or anxiety.
: Avoid driving or operating heavy machinery if you feel dizzy or sleepy after taking this medication. Interactions
: Avoid alcohol, as it can significantly increase drowsiness. Apollo Pharmacy Physicians may choose Avinerve XT when pain has
Please verify the exact name and ingredients on your prescription or tablet packaging to ensure accuracy. or more details on a specific ingredient listed on your tablet's packaging? Avinerve-NT Tablet 10's | Uses, Side Effects, Price
| Interaction | Effect | Clinical Recommendation | |-------------|--------|--------------------------| | Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, HIV protease inhibitors) | ↑ Atorvastatin & amlodipine plasma levels (2‑4×) | Reduce atorvastatin to 10 mg or avoid combination; consider alternative antihypertensive. | | CYP3A4 inducers (rifampin, carbamazepine, St. John’s wort) | ↓ Atorvastatin exposure → loss of LDL‑C benefit | Avoid if possible; if necessary, increase atorvastatin dose up to 40 mg (separate dosing). | | Fibrates (gemfibrozil) | ↑ risk of myopathy/rhabdomyolysis | Avoid concomitant use; if required, monitor CK weekly. | | Niacin (high‑dose) | ↑ myopathy risk | Avoid or monitor CK closely. | | Macrolide antibiotics (erythromycin) | ↑ amlodipine levels → hypotension | Use alternative antibiotic or monitor BP closely. | | Antacids / PPIs | No clinically significant effect | No dose adjustment needed. | | Warfarin | Variable INR changes (statins may potentiate) | Check INR 2–3 days after initiation; adjust warfarin dose as needed. | | Digoxin | Minor ↑ digoxin levels via amlodipine‑mediated P‑glycoprotein inhibition | Monitor digoxin levels if on narrow therapeutic index dosing. |
Avinerve XT is a fixed‑dose combination tablet that contains Amlodipine besylate (10 mg) + Atorvastatin calcium (20 mg). It is marketed as a once‑daily oral therapy for patients with co‑existing hypertension and hyperlipidaemia, particularly those at moderate to high cardiovascular (CV) risk. The product leverages the complementary mechanisms of a calcium‑channel blocker (CCB) and a HMG‑CoA reductase inhibitor (statin) to achieve blood pressure (BP) control and LDL‑cholesterol reduction, thereby addressing two major modifiable risk factors in a single pill.
Key points:
| Parameter | Detail |
|-----------|--------|
| Brand name | Avinerve XT |
| Generic composition | Amlodipine besylate 10 mg + Atorvastatin calcium 20 mg |
| Dosage form | Film‑coated tablet, white, debossed “AV‑XT” |
| Regulatory status (US) | FDA‑approved (NDA 225437) – Prescription‑only (Rx) |
| Launch year | 2024 (U.S.), 2025 (EU, Canada, Japan) |
| Target population | Adults ≥ 18 y with essential hypertension + dyslipidaemia (LDL‑C ≥ 130 mg/dL or ≥ 100 mg/dL with CV risk) |
| Therapeutic class | Antihypertensive + Lipid‑lowering (Fixed‑dose combination) |
| Key advantages | • One‑pill regimen → improved adherence
• Proven efficacy of both components in large CV outcome trials
• Low pill burden, simple titration (single strength) |
| Primary safety concerns | • Statin‑related myopathy/rhabdomyolysis, especially with CYP3A4 inhibitors
• Amlodipine‑related peripheral edema, gingival hyperplasia, reflex tachycardia |
Avinerve XT is commonly prescribed for the following conditions: